Association Between Change in Accelerometer-Measured and Self-Reported Physical Activity and Cardiovascular Disease in the Look AHEAD Trial
Look AHEAD Study Group, John M Jakicic, Robert I Berkowitz, Paula Bolin, George A Bray, Jeanne M Clark, Mace Coday, Caitlin Egan, Mary Evans, John P Foreyt, Janet E Fulton, Frank L Greenway, Edward W Gregg, Helen P Hazuda, James O Hill, Edward S Horton, Van S Hubbard, Robert W Jeffery, Karen C Johnson, Ruby Johnson, Steven E Kahn, Anne Kure, Wei Lang, Cora E Lewis, David M Nathan, Jennifer Patricio, Anne Peters, Xavier Pi-Sunyer, Henry Pownall, W Jack Rejeski, Monika Safford, Kerry J Stewart, Thomas A Wadden, Michael P Walkup, Rena R Wing, Holly Wyatt, Look AHEAD Study Group, John M Jakicic, Robert I Berkowitz, Paula Bolin, George A Bray, Jeanne M Clark, Mace Coday, Caitlin Egan, Mary Evans, John P Foreyt, Janet E Fulton, Frank L Greenway, Edward W Gregg, Helen P Hazuda, James O Hill, Edward S Horton, Van S Hubbard, Robert W Jeffery, Karen C Johnson, Ruby Johnson, Steven E Kahn, Anne Kure, Wei Lang, Cora E Lewis, David M Nathan, Jennifer Patricio, Anne Peters, Xavier Pi-Sunyer, Henry Pownall, W Jack Rejeski, Monika Safford, Kerry J Stewart, Thomas A Wadden, Michael P Walkup, Rena R Wing, Holly Wyatt
Abstract
Objective: To conduct post hoc secondary analysis examining the association between change in physical activity. Measured with self-report and accelerometry, from baseline to 1 and 4 years and cardiovascular disease (CVD) outcomes in the Look AHEAD Trial.
Research design and methods: Participants were adults with overweight/obesity and type 2 diabetes with physical activity. Data at baseline and year 1 or 4 (n = 1,978). Participants were randomized to diabetes support and education or intensive lifestyle intervention. Measures included accelerometry-measured moderate-to-vigorous physical activity (MVPA), self-reported physical activity, and composite (morbidity and mortality) CVD outcomes.
Results: In pooled analyses of all participants, using Cox proportional hazards models, each 100 MET-min/week increase in accelerometry-measured MVPA from baseline to 4 years was associated with decreased risk of the subsequent primary composite outcome of CVD. Results were consistent for changes in total MVPA (hazard ratio 0.97 [95% CI 0.95, 0.99]) and MVPA accumulated in ≥10-min bouts (hazard ratio 0.95 [95% CI 0.91, 0.98]), with a similar pattern for secondary CVD outcomes. Change in accelerometry-measured MVPA at 1 year and self-reported change in physical activity at 1 and 4 years were not associated with CVD outcomes.
Conclusions: Increased accelerometry-measured MVPA from baseline to year 4 is associated with decreased risk of CVD outcomes. This suggests the need for long-term engagement in MVPA to reduce the risk of CVD in adults with overweight/obesity and type 2 diabetes.
Trial registration: ClinicalTrials.gov NCT00017953.
© 2022 by the American Diabetes Association.
Source: PubMed